7+ hour, 18+ min ago  (272+ words) Updated Jun 25, 2026 06: 42 Trodelvy, a Trop-2-directed antibody-drug conjugate, is now approved either as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy or in combination with Keytruda for patients whose tumors express PD-L1 with a Combined…...